90Y‐ibritumomab tiuxetan in patients with extra‐nodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) — The Zeno Study.

⁹⁰Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study Keywords: 90Y-ibritumomab tiuxetan; extra-nodal marginal zone B-cell lymphoma; MALT lymphoma; relapsed; treatment-naïve EN 90Y-ibritumomab tiuxetan extra-nodal marginal zone B-cell lymphoma MALT lymphoma relapsed treatment-naïve e6 e9 4 03/31/20 20200401 NES 200401 Marginal zone lymphomas (MZL) represent about 17% of all non-Hodgkin lymphomas (NHL) (Zinzani & Broccoli, [8]) and are composed of three different entities: splenic MZL, nodal MZL and marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In conclusion, YIT represents a highly effective and tolerable treatment option for MALT lymphoma, in a setting where currently there are no standard treatments and the therapy options are limited, especially in R/R patients. [Extracted from the article]